Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (4r,5r)-5-(4-((4-(4-aza-1-azoniabicyclo(2.2.2)octan-1-ylmethyl)phenyl)methoxy)phenyl)-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-16-benzothiepin-4-ol
2. Livmarli
1. Lopixibat
2. Maralixibat [usan]
3. 716313-53-0
4. Maralixibat Cation
5. Livmarli
6. Uyb6uof69l
7. Lum001 Cation
8. Lum-001 Cation
9. Chembl363392
10. Maralixibat (usan)
11. 4-aza-1-azoniabicyclo(2.2.2)octane, 1-((4-((4-((4r,5r)-3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenoxy)methyl)phenyl)methyl)-
12. Lopixibat Cation
13. Chembl17879
14. Lum 001
15. 1-(4-((4-((4r,5r)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b]thiepin-5-yl)phenoxy)methyl)benzyl)-1,4-diazabicyclo[2.2.2]octan-1-ium
16. Unii-uyb6uof69l
17. Lopixibat (deleted Inn)
18. Maralixibat [who-dd]
19. Schembl10013954
20. Gtpl11708
21. Dtxsid001337103
22. Bdbm50140282
23. Compound 74 [pmid: 16134951]
24. D10951
25. Q27291331
26. (4r,5r)-5-[4-[[4-(4-aza-1-azoniabicyclo[2.2.2]octan-1-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1lambda6-benzothiepin-4-ol
27. 1-{4-[4-((4r,5r)-3,3-dibutyl-7-dimethylamino-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1h-1lambda*6*-benzo[b]thiepin-5-yl)-phenoxymethyl]-benzyl}-4-aza-1-azonia-bicyclo[2.2.2]octane; Chloride
Molecular Weight | 675.0 g/mol |
---|---|
Molecular Formula | C40H56N3O4S+ |
XLogP3 | 7.1 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 13 |
Exact Mass | 674.39915345 g/mol |
Monoisotopic Mass | 674.39915345 g/mol |
Topological Polar Surface Area | 78.5 Ų |
Heavy Atom Count | 48 |
Formal Charge | 1 |
Complexity | 1080 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Maralixibat is indicated in the treatment of cholestatic pruritus in patients with Alagille syndrome who are at least 1 year old.
Maralixibat is indicated in the treatment of cholestatic pruritus in patients with Alagille syndrome who are at least 1 year old. It has a moderate duration of action as it is given once daily, and a wide therapeutic index as patients have safely tolerated single doses up to 18 times the normal dose. Patients should be counselled regarding the risks of liver test abnormalities, gastrointestinal adverse reactions, and fat-soluble vitamin deficiencies.
Absorption
Maralixibat is not extensively absorbed. A single 30 mg dose of maralixibat given under fasted conditions reached a median Tmax of 0.75 hours, with a mean Cmax of 1.65 1.10 ng/mL, and a mean AUClast of 3.43 2.13 h\*ng/mL. In pediatric patients given a dose of 380 g/kg, the highest serum concentration was 5.93 ng/mL, but was <0.25 ng/mL in the majority of patients.
Route of Elimination
A 5 mg radiolabelled dose of maralixibat is 73% eliminated in feces and 0.066% eliminated in urine. 94% of the dose recovered in the feces was as the unmetabolized parent compound. <3% of the total dose is metabolized.
Maralixibat metabolites have not been identified in plasma, however 3 minor metabolites have been recovered in the feces. The structure of these metabolites have not been defined in the literature.
The mean half life of maralixibat is 1.6 hours.
Patients with Alagille syndrome experience potentially debilitating pruritus. The exact mechanism of cholestatic pruritus in Alagille syndrome is not well defined, however it is correlated with elevated total serum bile acid concentrations. Enterohepatic circulation involves the synthesis of bile acid from cholesterol in the liver, conjugation with glycine or taurine, excretion into the duodenum, 95% resorption in the distal ileum through the ileal bile acid transporter (IBAT), return to the liver via the portal vein, and uptake into the liver by the sodium-dependent taurocholate co-transporting peptide (NTCP). It is important to note that unconjugated bile acids may freely diffuse across the intestinal mucosa or be transported across by other organic anion transporters. Maralixibat reversibly inhibits IBAT to decrease bile acid resorption in the ileum, leading to decreased resorption of bile acids in the distal ileum, increased elimination of bile acids in the feces, and decreased serum bile acids. The mechanism of action of maralixibat also leads to increased rates of diarrhea in patients. Under normal conditions, bile acids binding to the farnesoid X receptor (FXR) in the liver by via nuclear receptor small heterodimer partner (SHP) or in the ileum via fibroblast growth factor 19 (FGF19), triggers signal cascade that inhibits CYP7A1-mediated bile acid synthesis. Inhibition of IBAT by maralixibat, inhibits these negative feedback loops, leading to increased bile acid synthesis, and a reduction of low density lipoprotein cholesterol. In one clinical trial (NCT02057692), not all dose strengths were associated with a clinically significant difference between maralixibat and placebo.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
ABOUT THIS PAGE
44
PharmaCompass offers a list of Maralixibat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Maralixibat manufacturer or Maralixibat supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Maralixibat manufacturer or Maralixibat supplier.
PharmaCompass also assists you with knowing the Maralixibat API Price utilized in the formulation of products. Maralixibat API Price is not always fixed or binding as the Maralixibat Price is obtained through a variety of data sources. The Maralixibat Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Maralixibat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Maralixibat, including repackagers and relabelers. The FDA regulates Maralixibat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Maralixibat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Maralixibat manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Maralixibat supplier is an individual or a company that provides Maralixibat active pharmaceutical ingredient (API) or Maralixibat finished formulations upon request. The Maralixibat suppliers may include Maralixibat API manufacturers, exporters, distributors and traders.
click here to find a list of Maralixibat suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Maralixibat as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Maralixibat API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Maralixibat as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Maralixibat and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Maralixibat NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Maralixibat suppliers with NDC on PharmaCompass.
Maralixibat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Maralixibat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Maralixibat GMP manufacturer or Maralixibat GMP API supplier for your needs.
A Maralixibat CoA (Certificate of Analysis) is a formal document that attests to Maralixibat's compliance with Maralixibat specifications and serves as a tool for batch-level quality control.
Maralixibat CoA mostly includes findings from lab analyses of a specific batch. For each Maralixibat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Maralixibat may be tested according to a variety of international standards, such as European Pharmacopoeia (Maralixibat EP), Maralixibat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Maralixibat USP).